Dexamethasone prevents the decrease of bone mineral density in type II collagen-induced rat arthritis model.
This study demonstrated the decrease of bone mineral density (BMD) in the type II collagen (CII)-induced arthritis (CIA) model in rats and the relationship between BMD and paw edema and the effect of dexamethasone-21-phosphate (DEX). The paw swelling occurred on Day 10 and reached its peak on Day 18 after CII injection. BMD in the CII-injected group is lower than that in the control group. BMD in the proximal and distal regions of the femur largely decreased in comparison with that of the middle region. The oral administration of DEX (0.1 mg/kg) inhibited the swelling and decrease of BMD in all three regions of the femur.
Takagi
T
T
Tanabe Seiyaku Co., Ltd., Discovery Research Laboratory, Osaka, Japan.
Tsao
P W
PW
Totsuka
R
R
Suzuki
T
T
Murata
T
T
Takata
I
I
D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001168:Arthritis / Q000097:blood / Q000139:chemically induced / Q000517:prevention & control*; D015415:Biomarkers / Q000097:blood; D015519:Bone Density / Q000187:drug effects*; D003094:Collagen / Q000008:administration & dosage / Q000009:adverse effects*; D003907:Dexamethasone / Q000494:pharmacology* / Q000627:therapeutic use; D015232:Dinoprostone / Q000097:blood; D004195:Disease Models, Animal; D004487:Edema / Q000139:chemically induced / Q000517:prevention & control; D005260:Female; D005269:Femur / Q000187:drug effects / Q000503:physiopathology; D005528:Foot / Q000473:pathology; D006614:Hindlimb; D006651:Histocytochemistry; D051381:Rats; D011917:Rats, Inbred Lew; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D003907:Dexamethasone; D003094:Collagen; D015232:Dinoprostone